Characterization of phenotypic and genotypic drug resistance patterns of *Mycobacterium tuberculosis* isolates from a city in Mexico

Samantha Flores-Treviño a, Rayo Morfin-Otero b, Eduardo Rodríguez-Noriega b, Esteban González-Díaz b, Héctor Raúl Pérez-Gómez b, Soraya Mendoza-Olazarán a, Isaías Balderas-Rentería c, Gloria María González d, Elvira Garza-González a,e,∗

a Servicio de Gastroenterología, Hospital Universitario Dr. José Eulogio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico
b Hospital Civil de Guadalajara, Fray Antonio Alcalde, y el Instituto de Patología Infecciosa y Experimental, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
c Laboratorio de Ingeniería Genética y Genómica, Facultad de Ciencias Químicas, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico
d Departamento de Microbiología, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico
e Departamento de Patología Clínica, Hospital Universitario Dr. José Eulogio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico

**A R T I C L E   I N F O**

Article history:
Received 19 November 2013
Accepted 13 April 2014
Available online 18 June 2014

Keywords:
Multidrug-resistant
*Mycobacterium tuberculosis*
Mutation
Isoniazid
Rifampicin

**A B S T R A C T**

Introduction: The emergence of multidrug-resistant (MDR) *Mycobacterium tuberculosis* strains has become a worldwide health care problem, making treatment of tuberculosis difficult. The aim of this study was to determine phenotypic resistance and gene mutations associated with MDR of clinical isolates of *Mycobacterium tuberculosis* from Guadalajara, Mexico.

Methods: One hundred and five isolates were subjected to drug susceptibility testing to first line drugs using the proportion and Mycobacteria Growth Indicator Tube (MGIT) methods. Genes associated with isoniazid (*inhA*, *katG*, *ahpC*) and rifampicin (*rpoB*) resistance were analyzed by either pyrosequencing or PCR-RFLP.

Results: Resistance to any drug was detected in 48.6% of isolates, of which 40% were isoniazid-resistant, 20% were rifampicin-resistant and 19% were MDR. Drug-resistant isolates had the following frequency of mutations in *rpoB* (48%), *katG* (14%), *inhA* (26%), *ahpC* (26%). Susceptible isolates also had a mutation in *ahpC* (29%).

Conclusions: This is the first analysis of mutations associated with MDR of *M. tuberculosis* in Guadalajara. Commonly reported mutations worldwide were found in *rpoB*, *katG* and *inhA* genes. Substitution C to T in position −15 of the *ahpC* gene may possibly be a polymorphism.

© 2013 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

**C a r a c t e r i z a c i ó n   d e   l o s   p a t r o n e s   d e   f a r m a c o r e s i s t e n c i a   f e n o t í p i c a   y   g e n o t í p i c a   d e   a i s l a m i e n t o s   d e   M y c o b a c t e r i u m   t u b e r c u l o s i s   d e   u n a   c i d a d   d e   M é x i c o**

**R E S U M E N**

Introducción: La emergencia de cepas de *Mycobacterium tuberculosis* multifarmacorresistentes (MFR) se ha convertido en un problema de salud mundial, dificultando el tratamiento de la tuberculosis. El objetivo de este estudio fue determinar la resistencia fenotípica y las mutaciones en genes asociados a MFR en aislamientos clínicos de *M. tuberculosis* de Guadalajara, México.

Métodos: Se determinó la susceptibilidad a fármacos de primera línea de 105 aislamientos, usando los métodos de proporciones y MGIT. Los genes asociados a resistencia a isoniazida (*inhA*, *katG*, *ahpC*) y a rifampicina (*rpoB*), se analizaron por pirosecuenciación o por PCR-RFLP.

Resultados: Se detectó la resistencia a cualquier fármaco en 48.6% de los aislamientos, 40% fueron resistentes a isoniazida, 20% fueron resistentes a rifampicina y 19% fueron MDR. Los aislamientos farmacoresistentes presentaron la siguiente frecuencia de mutaciones en *rpoB* (48%), *katG* (14%), *inhA* (26%), *ahpC* (26%). Además, los aislamientos susceptibles también mostraron una mutación en *ahpC* (29%).

∗ Corresponding author.

E-mail address: elvira_garza_gzz@yahoo.com (E. Garza-González).

http://dx.doi.org/10.1016/j.eimc.2014.04.005
0213-005X/© 2013 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.
Introduction

Tuberculosis (TB) is an important death-causing disease, considered to be the second leading cause of death from an infectious disease worldwide. Despite the availability of highly efficacious treatment for decades, TB remains a major global health problem. The World Health Organization (WHO) estimates that about one-third of the global population is infected with *Mycobacterium tuberculosis.* In Mexico, more than two thousand people die of this disease every year and the TB rate per 100,000 population was 16.8 in 2010. In Jalisco, the TB rate was 13 per 100,000 population. These data render tuberculosis an important public health problem in this state that deserves special attention.

One of the most alarming trends concerning TB is the emergence of multidrug-resistant strains of *M. tuberculosis* (MDR-TB), defined as resistant to at least isoniazid (INH) and rifampicin (RIF), which has been steadily increasing over the years, making treatment of TB difficult. Thus, it is important to identify resistant strains as soon as possible to allow adjustments in treatment and minimize transmission. Drug resistance (DR) in *M. tuberculosis* is caused by mutations in conserved regions of the genome. RIF-resistance is mainly caused by mutations in the β subunit of the RNA polymerase, which is encoded by the *rpoB* gene. More than 95% of resistant strains harbor mutations within the rifampicin resistance determining region (RRDR), an 81-bp hot-spot (codons 507–533) of *rpoB*, the most common of which occur at codons 526 and 531. Mutations in the catalase peroxidase gene (*katG*) and in a gene encoding the enoyl acyl carrier protein reductase (*inhA*) have been found to account for 40–60% and 20–34% of INH-resistant *M. tuberculosis* strains, respectively. Similarly, mutations in the intergenic region oxyR-ahpC can reduce the level of expression of *inhA* and have been associated with INH-resistance (10–15%).

DR tuberculosis is a serious public health issue, especially in developing countries. To solve this problem it is necessary to carry out surveillance of resistance patterns and the mutations associated to this resistance. Some studies in Mexico have analyzed the frequency of gene mutations associated with drug resistance of clinical isolates of *M. tuberculosis.* Guadalajara, Jalisco is one region that has not been studied. The aim of this study is to determine phenotypic resistance to first-line drugs and gene mutations associated with INH and RIF resistance of clinical isolates of *M. tuberculosis* in Guadalajara, Mexico.

Materials and methods

Clinical specimens and isolates

The Hospital Civil de Guadalajara, Fray Antonio Alcalde, admits >240 patients suspected of having tuberculosis per year (2005–2011). Beginning in September 2010 to November 2011, three hundred and fifty one specimens were collected. Samples were decontaminated by modified Petroff’s method and cultured on Löwestein-Jensen slants at 37 °C. Smears were made and stained by the Ziehl Neelsen staining method and examined for the presence of acid-fast bacilli (AFB). The resulting isolates were identified by traditional biochemical tests, niacin production and nitrate reduction. The local ethics committee approved this study (MB11-005) and informed consent was obtained from patients.

DNA isolation

A loopful of bacterial colony suspended in 1 mL of sterile water was first inactivated at 80 °C for 1 h. The suspensions were then centrifuged at 8000 rpm for 5 min. Supernatants were discarded and pellets resuspended in 200 μL of 100 mM Tris–HCl and incubated with lysozyme (1 mg/mL) at 37 °C overnight followed by incubation with 1% SDS and protease K (10 mg/L) at 55 °C for 2 h. DNA was then extracted using a phenol extraction, ethanol precipitation method.

Molecular identification of *M. tuberculosis* strains

Species identification was performed using multiplex PCR amplification of *cfp32, RD9 and RD12.* Primer pairs for *cfp32* (5′-ATGCCCCAGAGGCGATACGCCAAT-3′ and 5′-CTATTGGATGCGTGCTTGTTCCA-3′), *RD9* (5′-TGCCGCTGGCGATGTCG-3′ and 5′-TTGGGGAGCGGGGGTTGTGATA-3′) and *RD12* (5′-GAGGGCGTTAATATCCGCTCTCAT-3′ and 5′-GCGAAATGCGGC-3′) were used as a primer mixture for three simultaneous PCRs in one tube. The reaction mixture contained 1X PCR buffer, 2 mM MgCl₂, 0.2 mM of each dNTP, 2.5 μL of dimethyl sulfoxide, 750 nM each of *cfp32* primers (Rv0577F and Rv0577R), 250 nM each of RD primers (Rv2073F3, Rv2073R3, Rv3120F and Rv3120R), 1 U of AmpliTaq polymerase (Bioline USA Inc., Randolph, MA, USA) and 200 ng of DNA. PCR was initiated by denaturation for 1 min at 96 °C, followed by 35 cycles of 10 s at 96 °C, 20 s at 60 °C and 1 min at 72 °C with final extension for 5 min at 72 °C. With this PCR, an isolate possessing all three regions can be identified as *M. tuberculosis.*

Phenotypic drug susceptibility testing

Drug susceptibility testing (DST) of all *M. tuberculosis* isolates was performed using two methods. The indirect proportion method on Löwestein-Jensen slants was performed as described previously with the following critical concentrations: STR 40 μg/mL, INH 0.2 μg/mL, RIF 40 μg/mL, EMB 2.0 μg/mL. Drug resistance was expressed as the proportion of colonies that grow on drug containing medium to drug-free medium and the critical proportion for resistance was 1% for all drugs. The manual MGIT method was performed using the following critical concentrations: STR 0.8 μg/mL, INH 0.1 μg/mL, RIF 1.0 μg/mL, EMB 3.5 μg/mL, according to the protocol provided by the manufacturers (Becton Dickinson, Sparks, MD). Fluorescence indicating microbial growth was detected with a 365-nm UV light from a transiluminator. When discordant results were found in both methods, testing was repeated. Strain H37Rv was used as control. Physicians in charge of TB patients were informed of all the DST results as soon as they were available. These results were then used to modify drug management of the patients accordingly.

Amplification of *rpoB, inhA, ahpC and katG* genes

Genes associated to INH and RIF resistance were amplified as described previously with the following primers: *rpoB*: 5′-CGG-ATCAAGGAGTCTT and biotin labeled 5′-CGATCAGACCGATGTTGC;
The IBM SPSS statistical software for Windows (SPSS version 20.0; SPSS Inc, Chicago, IL, USA) was used in this analysis.

Results

Prevalence of M. tuberculosis and drug resistance by both methods

Of the 351 clinical samples processed, 96 (27.4%) were AFB smear-positive specimens and 105 isolates were identified as M. tuberculosis by both biochemical and molecular tests. In addition, 1 (0.9%) isolate was identified as M. bovis and 6 (5.4%) isolates were identified as nontuberculous mycobacteria (NTM) by biochemical and molecular tests.

Drug susceptibility data for the four drugs tested are shown in Table 1, where results from proportion and MGIT methods were compared. INH resistance was detected in 42 (40%) isolates (n = 28, 26.6% by the proportions method). RIF resistance was detected in 21 (20%) isolates (n = 19, 18.1% by the proportions method). MDR was detected in 20 (19%) isolates (n = 18, 17.1% by the proportions method). Overall, the MGIT method showed a higher detection level. When comparing methods, RIF and STR resistance results showed excellent concordance (κ = 0.969 and κ = 0.950, respectively) whereas INH and EM resistance results showed strong concordance (κ = 0.666 and κ = 0.744, respectively). In general, SIRE analysis showed strong concordance (κ = 0.639).

Resistance associated mutations

Ser531Leu mutation in rpoB was detected in 10 out of 21 (48%) RIF-resistant isolates (p < 0.0001), all MDR by both drug susceptibility testing methods (Table 2). Among the 42 INH-resistant isolates (MGIT method), 6 (14%) had a mutation in codon 315 of the katG gene (p < 0.05) and 11 (26%) were mutated in the inhA gene (p < 0.05); 10 had a→C; T→ substitution and one had a→C; T substitution. None of these isolates were mutated in the katG gene; however, 5 had an ahpC mutation and 8 also had mutation in rpoB. All isolates (21%) that had both inhA and rpoB mutations were MDR (Table 2).

Mutations in the ahpC gene were found in both INH susceptible (n = 18, 29%) and resistant isolates (n = 11, 26%) (p = 0.9645). Two site mutations were detected, both at C→T substitutions, situated at positions –15 and –10 in the promoter region.

<table>
<thead>
<tr>
<th>Drug resistance</th>
<th>n (%) of strains</th>
</tr>
</thead>
<tbody>
<tr>
<td>INH</td>
<td>39 (39.2)</td>
</tr>
<tr>
<td>RIF</td>
<td>1 (1.0)</td>
</tr>
<tr>
<td>STR</td>
<td>1 (1.0)</td>
</tr>
<tr>
<td>EMB</td>
<td>1 (1.0)</td>
</tr>
<tr>
<td>MDR</td>
<td>2 (2.0)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug resistance</th>
<th>n (%) of strains</th>
</tr>
</thead>
<tbody>
<tr>
<td>INH</td>
<td>20 (69.7)</td>
</tr>
<tr>
<td>RIF</td>
<td>3 (10.0)</td>
</tr>
<tr>
<td>STR</td>
<td>2 (6.7)</td>
</tr>
<tr>
<td>EMB</td>
<td>1 (3.3)</td>
</tr>
<tr>
<td>MDR</td>
<td>1 (3.3)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug resistance</th>
<th>n (%) of strains</th>
</tr>
</thead>
<tbody>
<tr>
<td>INH</td>
<td>18 (17.1)</td>
</tr>
<tr>
<td>RIF</td>
<td>2 (1.9)</td>
</tr>
<tr>
<td>STR</td>
<td>3 (2.9)</td>
</tr>
<tr>
<td>EMB</td>
<td>1 (0.9)</td>
</tr>
<tr>
<td>MDR</td>
<td>1 (0.9)</td>
</tr>
</tbody>
</table>

4 INH: isoniazid; RIF: rifampin; STR: streptomycin; EMB: ethambutol; MDR: multiple drug resistance.

5 MGIT: Mycobacteria Growth Indicator Tube.
Discussion

This is the first analysis of phenotypic resistance to first-line drugs and mutations associated with INH and RIF-resistance of clinical isolates of M. tuberculosis in Guadalajara, Jalisco, Mexico.

When we analyzed proportions and MGIT methods for DST, both showed similar resistance patterns and strong concordance when detecting MDR. The MGIT method showed higher detection levels of INH resistance. In addition, we detected a MDR rate (19%) lower than that previously reported (38%).<sup>22</sup> *rpoB*31 is the most frequent mutation among RIF-resistant isolates worldwide<sup>23</sup> including Mexico.<sup>5–13</sup> Other commonly RIF-resistant associated mutations are *rpoB*516 and *rpoB*526.<sup>5,7,12,13</sup> Nevertheless, we detected *rpoB*531 mutation only in half of the RIF-resistant isolates. The use of a 57-bp region rather than the entire 81-bp hotspot of *rpoB* may explain this relatively low proportion of RIF-resistant strains with *rpoB* mutations in the current study. In addition, mutations outside RRDR have also been found in RIF-resistant isolates worldwide,<sup>23</sup> including Mexico<sup>6,8,10</sup>; therefore, some of the RIF-resistant isolates that did not show a mutation may have a mutation in these regions. Further analysis of the whole RRDR region of these isolates may help detect other mutations.

It has been demonstrated that almost all RIF-resistant strains also show resistance to other drugs, mainly to INH.<sup>24</sup> In fact, RIF-resistant detection has been proposed as an early indicator of MDR-TB. Our results show that almost all (95%) RIF-resistant isolates analyzed were also INH-resistant. To delineate such role, we need to run more clinical specimens to define if the *rpoB* gene could be used as a surrogate marker to early detect MDR-TB.

An unusually low frequency of *katG* mutations (14%) in INH-resistant isolates was found in our study. Although it has been reported that *katG*315 mutation can account for less than a quarter of *katG* mutations in INH resistant strains,<sup>25</sup> mutations at different sites other than the 315 codon of the *katG* gene may be present in our INH resistant isolates.<sup>8–11,14</sup> Other strategies such as complete sequencing of *katG* may be helpful in defining the mutations associated to INH resistance.

As expected, we found a frequency of mutations (26%) in the promoter region of *inhA* similar to data reported before, which is 20–34% of INH-resistant strains.<sup>3,4</sup> To the best of our knowledge, only three other studies have reported *inhA* mutations in Mexico, all of which shared the same mutation we found.<sup>5,12,13</sup>

In our study, both INH susceptible and resistant isolates were found to be mutated in the *ahpC* gene. Although initially *ahpC* was associated to INH resistance,<sup>26</sup> reports of *ahpC* promoter mutations together with *katG* deletion indicate an increase in the expression of *ahpC* as a compensatory mutation for the loss of catalase/peroxidase activity rather than the cause of INH resistance directly.<sup>4,27</sup> Additionally, INH susceptible strains harboring an *ahpC* mutation have been reported before, in positions such as −32 and −10.<sup>12,28</sup> Consequently, this sequence alteration has been suggested to actually be a polymorphism.<sup>29</sup> Considering we did not have deletion of *katG*, our results strongly support this idea.

Almost half of INH-resistant isolates (48%) in our study did not have any mutation at all. Thus, further research is needed to expand the analysis of regions of both *katG* and *inhA*, in search of additional mutations.

In conclusion, this is the first analysis of mutations associated with INH and RIF-resistance of clinical isolates of M. tuberculosis in Guadalajara, Jalisco, Mexico, where most commonly reported mutations worldwide were detected. Additionally, fingerprinting (IS6110-RFLP and spoligotyping) patterns analysis would determine if these isolates belong in the same cluster. The evaluation of different DR profiles and resistance-associated mutations in the same cluster could determine whether mutations were acquired independently, or whether there is a presence and dissemination of a successful clone in the Guadalajara community; thus the analysis of clone polymorphisms in this population is imperative. This is an ongoing research by our group.

Conflict of interest

The authors declare no conflict of interest.

References


---

Table 2

<table>
<thead>
<tr>
<th>Isolates n (%)</th>
<th>Mutations detected</th>
<th>Resistance patterns (SIRE)(^a)</th>
<th>Proportion method</th>
<th>MGIT method(^b)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>INH</td>
<td>RIF</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>katG</em></td>
<td><em>ahpC</em></td>
<td><em>inhA</em></td>
<td><em>rpoB</em></td>
</tr>
<tr>
<td>12(11)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4(3.8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3(2.9)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3(2.9)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3(2.9)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2(1.9)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1(0.95)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1(0.95)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1(0.95)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1(0.95)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1(0.95)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1(0.95)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^a\) SIRE: streptomycin, isoniazid, rifampin, and ethambutol; R (RIF): rifampicin; E: ethambutol; I (INH): isoniazid; S: streptomycin.

\(^b\) MGIT: Mycobacteria Growth Indicator Tube.


